Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma

被引：0
|
作者：
Campbell, Katie M.
Bustami, Zaid
Chen, Daniel G.
Medina, Egmidio
Gonzalez, Cynthia R.
Aldeen, Nataly Naser
Baselga-Carretero, Ignacio
Vega-Crespo, Agustin
Maxey, Jessica
Chen, Jia M.
Kuklinski, Lawrence F.
Kendra, Kari L.
Chmielowski, Bartosz
Thach-Giao Truong
Khushalani, Nikhil I.
Collichio, Frances
Ikeguchi, Alexandra
Victor, Adrienne I.
Margolin, Kim
Sosman, Jeffrey A.
Patel, Sapna P.
Hu-Lieskovan, Siwen
Moon, James
Bellasea, Shay
Wells, Daniel K.
Spencer, Christine N.
Thompson, Marshall A.
Wu, Michael
Scumpia, Philip O.
VanderWalde, Ari
Ribas, Antoni
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6550
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma A Meta-Analysis
    Serritella, Anthony V.
    Shenoy, Niraj K.
    JAMA ONCOLOGY, 2023, 9 (10) : 1441 - 1446
  • [32] A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma
    Shalhout, Sophia Z.
    Emerick, Kevin S.
    Kaufman, Howard L.
    Silk, Ann W.
    Thakuria, Manisha
    Miller, David M.
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (07) : 299 - 302
  • [33] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
    Klee, Gina
    Kurzhals, Jonas
    Hagelstein, Victoria
    Zillikens, Detlef
    Recke, Andreas
    Langan, Ewan A.
    Terheyden, Patrick
    MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471
  • [34] ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
    Butler, M. O.
    Robert, C.
    Negrier, S.
    In, G. K.
    Walker, J.
    Krajsova, I.
    Atkinson, V. G.
    Hansson, J.
    Kapiteijn, E.
    Loquai, C.
    Shaw, H. M.
    Cheng, T.
    Mansard, S.
    Grob, J. J.
    Guidoboni, M.
    Mehta, M.
    Ascierto, P. A.
    Diab, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
    Di Giacomo, A. M.
    Simonetti, E.
    Calabro, L.
    Vegni, V.
    Santangelo, F.
    Depenni, R.
    Colucci, M.
    Valente, M.
    Grifoni, R.
    Lofiego, M. F.
    Amato, G.
    Keer, H. N.
    Oganesian, A.
    Chan, D.
    Giannarelli, D.
    Altomonte, M.
    Ceccarelli, M.
    Anichini, A.
    Covre, A.
    Maio, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1237 - 1237
  • [36] Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
    D'Angelo, Sandra P.
    Larkin, James
    Sosman, Jeffrey A.
    Lebbe, Celeste
    Brady, Benjamin
    Neyns, Bart
    Schmidt, Henrik
    Hassel, Jessica C.
    Hodi, F. Stephen
    Lorigan, Paul
    Savage, Kerry J.
    Miller, Wilson H., Jr.
    Mohr, Peter
    Marquez-Rodas, Ivan
    Charles, Julie
    Kaatz, Martin
    Sznol, Mario
    Weber, Jeffrey S.
    Shoushtari, Alexander N.
    Ruisi, Mary
    Jiang, Joel
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 226 - +
  • [37] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Long, G. V.
    Larkin, J.
    Ascierto, P. A.
    Hodi, F. S.
    Rutkowski, P.
    Sileni, V.
    Hassel, J.
    Lebbe, C.
    Pavlick, A. C.
    Wagstaff, J.
    Schadendorf, D.
    Dummer, R.
    Hogg, D.
    Haanen, J. B. A. G.
    Corrie, P.
    Hoeller, C.
    Horak, C.
    Wolchok, J.
    Robert, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] PD-L1 EXPRESSION AS A BIOMARKER FOR NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) AND NIVO ALONE IN ADVANCED MELANOMA (MEL): A POOLED ANALYSIS
    Long, Georgina
    Larkin, James
    Ascierto, Paolo
    Hodi, Stephen
    Rutkowski, Piotr
    Chiarion-Selini, Vanna
    Hassel, Jessica
    Lebbe, Celeste
    Pavlick, Anna
    Wagstaff, John
    Schadendorf, Dirk
    Dummer, Reinhard
    Hogg, David
    Haanen, John
    Corrie, Pippa
    Hoeller, Christopher
    Horak, Christine
    Wolchok, Jedd
    Robert, Caroline
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 126 - 126
  • [39] Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients.
    Brunot, Angelique
    Jeudy, Geraldine
    Tas, Mathieu
    Guillot, Bernard
    Kramkimel, Nora
    Mortier, Laurent
    Mansard, Sandrine
    Lebbe, Celeste
    Blom, Astrid
    Le Corre, Yannick
    Montaudie, Henri
    Prey, Sorilla
    Campillo-Gimenez, Boris
    Lesimple, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
    Menzies, A. M.
    Johnson, D. B.
    Ramanujam, S.
    Atkinson, V. G.
    Wong, A. N. M.
    Park, J. J.
    McQuade, J. L.
    Shoushtari, A. N.
    Tsai, K. K.
    Eroglu, Z.
    Klein, O.
    Hassel, J. C.
    Sosman, J. A.
    Guminski, A.
    Sullivan, R. J.
    Ribas, A.
    Carlino, M. S.
    Davies, M. A.
    Sandhu, S. K.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 368 - 376
12345